10 Biotechnology Stocks to Sell Now

Advertisement

This week, the overall grades of 10 biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

KYTHERA Biopharmaceuticals, Inc.’s (KYTH) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. KYTHERA Biopharmaceuticals focuses on the discovery, development, and commercialization of prescription products for the aesthetic medicine market. In Portfolio Grader’s specific subcategories of Equity and Cash Flow, KYTH also gets F’s. As of Jan. 27, 2015, 20.1% of outstanding KYTHERA Biopharmaceuticals, Inc. shares were held short. To get an in-depth look at KYTH, get Portfolio Grader’s complete analysis of KYTH stock.

This is a rough week for ARIAD Pharmaceuticals, Inc. (ARIA). The company’s rating falls to D from the previous week’s C. ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. The stock gets F’s in Equity, Cash Flow and Sales Growth. As of Jan. 27, 2015, 24.6% of outstanding ARIAD Pharmaceuticals, Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of ARIA stock.

Slipping from a C to a D rating, Trius Therapeutics, Inc. (TSRX) takes a hit this week. Trius Therapeutics is a biopharmaceutical company. The stock receives F’s in Earnings Growth, Earnings Momentum and Equity. Cash Flow and Sales Growth also get F’s. To get an in-depth look at TSRX, get Portfolio Grader’s complete analysis of TSRX stock.

Vical Incorporated (VICL) earns a D this week, moving down from last week’s grade of C. Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of VICL stock.

The rating of Raptor Pharmaceutical (RPTP) declines this week from a C to a D. Raptor Pharmaceutical researches existing drugs to improve them through specialized drug targeting methods and formulation changes. The stock gets F’s in Equity and Cash Flow. As of Jan. 27, 2015, 23.4% of outstanding Raptor Pharmaceutical shares were held short. To get an in-depth look at RPTP, get Portfolio Grader’s complete analysis of RPTP stock.

CTI BioPharma Corp.’s (CTIC) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). Cell Therapeutics develops, acquires, and sells new treatments for cancer. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of CTIC stock.

Tenax Therapeutics, Inc.’s (TENX) rating weakens this week, dropping to an F versus last week’s D. The stock gets F’s in Earnings Momentum, Earnings Revisions and Equity. Cash Flow and Sales Growth also get F’s. The stock currently has a trailing PE Ratio of 110.00. To get an in-depth look at TENX, get Portfolio Grader’s complete analysis of TENX stock.

The rating of Orexigen Therapeutics, Inc. (OREX) slips from a C to a D. Orexigen Therapeutics is focused on the development and commercialization of pharmaceutical products for the treatment of the central nervous system disorders with an initial focus on obesity. The stock gets F’s in Equity and Cash Flow. As of Jan. 27, 2015, 29% of outstanding Orexigen Therapeutics, Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of OREX stock.

This week, Peregrine Pharmaceuticals, Inc.’s (PPHM) rating worsens to a D from the company’s C rating a week ago. Peregrine Pharmaceuticals is a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections. The stock gets F’s in Equity, Cash Flow and Sales Growth. To get an in-depth look at PPHM, get Portfolio Grader’s complete analysis of PPHM stock.

Hyperion Therapeutics, Inc. (HPTX) gets weaker ratings this week as last week’s C drops to a D. Hyperion Therapeutics develops therapeutics to treat disorders in the areas of orphan diseases and hepatology. The stock receives F’s in Earnings Growth, Earnings Momentum, Earnings Revisions and Margin Growth. For more information, get Portfolio Grader’s complete analysis of HPTX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/01/10-biotechnology-stocks-to-sell-now-kyth-aria-tsrx/.

©2024 InvestorPlace Media, LLC